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ORIGINAL RESEARCH ARTICLE Open Access
Pilot Study of Dose–Response Effects of Exercise
on Change in C-Reactive Protein, Cortisol,
and Health-Related Quality of Life Among
Cancer Survivors
Jeanette M. Ricci,1 Victoria Flores,2 Isabela Kuroyama,3 Arash Asher,4 and Heather P. Tarleton1,*
Abstract
Fatigue, stress, and depression contribute to poor health-related quality of life (HRQoL) among cancer survivors.
This study examined the effects of combined aerobic and resistance training (CART) on HRQoL and biomarkers of
stress. Cancer survivors (n = 76, 91% female, 39% breast cancer, 32% gynecologic cancer) were enrolled in CART
for three 60-min sessions, weekly, for 26 weeks. Participants completed the National Institutes of Health’s Patient
Reported Outcomes Measurement Information System (NIH PROMIS) fatigue assessment and the SF-36. Cor-
tisol and c-reactive protein (CRP) were assessed using volunteered blood specimens. Baseline fatigue scores
were worse for participants completing treatment within the last year, compared to long-term survivors
[F = (2, 59) = 3.470, p = 0.038]. After 26 weeks, fatigue scores improved by a noteworthy two points [M = 52.72,
standard deviation, SD = 10.10 vs. M = 50.67, SD = 10.14; t(48) = 1.7145, p = 0.092]. Pre- to postintervention im-
provements in bodily pain [M = 50.54, SD = 9.51 vs. M = 48.20, SD = 10.07; t(33) = 2.913, p = 0.006] and limitations
in social functioning [M = 50.60, SD = 9.17 vs. M = 47.75, SD = 11.66; t(33) = 2.206, p = 0.034], as well as a mean de-
crease of 1.64 – 10.11 mg/L in CRP levels [t(107) = 1.261, p = 5.965], were observed. Participants within 1 year of
treatment completion experienced greater improvements in post CRP levels compared to those who had treat-
ment 1–4 years ( p = 0.030) and 5 or more years ago ( p = 0.023). Physical functioning, fatigue, fear/anxiety, social
role satisfaction, and CRP levels improved following participation in this exercise intervention. Oncologists should
consider recommending CART as soon as medically feasible following the cessation of cancer treatment.
Keywords: aerobic and resistance training; cancer survivors; c-reactive protein; cortisol; fatigue; health-related
quality of life
Background
Medical advances will lead to a larger population of
aging adults who can be classified as cancer survivors
and who may face challenges such as worsening health-
related quality of life (HRQoL).1 After treatment, survi-
vors experience depression, fatigue and poor motivation
to engage physically in daily activities and may develop
anxiety and fear with as many as 19% of survivors
reportedly meeting the criteria for post-traumatic
stress disorder.2 Survivors with untreated fatigue and
stress are less likely to adhere to recommended cancer
surveillance and are less likely to engage in health-
promoting activities.3
Physical activity is linked to increased functional ca-
pacity, improved mood, increased immune function,
decreased fatigue, improved health perceptions, and
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improved HRQoL.4,5 From a psychosocial perspective,
participating in physical activity provides a positive feed-
back loop as the cancer survivor sees his/her body respond
and engage successfully in exercise.6 From a biological
perspective, exercise has been suggested to reduce stress
and chronic inflammation.7 Stress and chronic inflamma-
tion are indicated by high levels of cortisol and c-reactive
protein (CRP), respectively. Abnormally high cortisol lev-
els can also disrupt the hypothalamic-pituitary-adrenal
axis and contribute to an increase in CRP.8 High levels
of CRP are associated with poor HRQoL, impaired phys-
ical function, and fatigue in cancer survivors.9,10
The Improving Physical Activity After Cancer
Treatment Study
Previously published studies of exercise interventions
in cancer survivors focused on one exercise modality,
often in a short (e.g., 12-week) intervention period.4
This study’s exercise prescription uses a combined aer-
obic and resistance training (CART) protocol with the
addition of core strengthening and flexibility over a 26-
week intervention period.
Data collected and pooled from two cohorts of can-
cer survivors that participated in the 26-week exercise
program were used to determine whether there is a
dose–response relationship between participation in
exercise training and changes in self-reported
HRQoL. The study also aimed to strengthen the
existing body of literature by adding pre- and postinter-
vention measurement of cortisol and CRP to assess
whether there is a dose–response relationship between
participation in exercise training and change in physi-
ological stress and inflammation, respectively.
Materials and Methods
Study population
The Improving Physical Activity After Cancer Treat-
ment (IMPAACT) Study was designed as a prospective
study of the effect of participation in a 26-week exercise
training program on the health of cancer survivors. The
study was approved by the Loyola Marymount Univer-
sity Institutional Review Board (LMU IRB 2014 SP
27 and LMU IRB 2015 SP 23) and the California Health
and Human Services Agency Institutional Review
Board (Protocol ID 14-02-1507) in accordance with
the Helsinki Declaration of 1975, as revised in 1983,
and the Declaration of the World Medical Association.
Two cohorts of cancer survivors were recruited
(Cohort #1, n = 33 and Cohort #2, n = 43) at two time-
points by convenience sampling using survey distribu-
tion in Los Angeles County, cancer survivor support
group referral, and physician referral. Written informed
consent was ascertained before study enrollment. Individ-
uals had to meet the following criteria to be eligible for
participation: primary diagnosis of cancer, treatment com-
pleted at any point before the study, and physical ability to
partake in moderate-intensity weight-bearing exercise.
Participants were excluded from the study if they
presented with any of the following conditions: preg-
nancy, stroke, or heart attack within past 6 months
and lymphedema. Participants were asked to inform
their physicians of their planned participation and to
review the exercise and assessment protocols with
their physicians before the intervention.
Assessments
Demographics, NIH PROMIS, and SF-36. At recruit-
ment, participants self-reported demographics, comor-
bidities, health behaviors, and perception of physical
activity level. Participants’ height and weight were col-
lected by trained researchers to compute body mass
index (BMI), in addition to completing waist cir-
cumference measurements. Participants’ HRQoL was
assessed using the fatigue domain of the National Insti-
tutes of Health’s Patient Reported Outcomes Measure-
ment Information System, version 1.0 (NIH PROMIS)
and the 36-item short-form survey, version 2.0 (SF-36).
Participants completed the NIH PROMIS fatigue as-
sessment, a subcomponent of the physical function do-
main with applicability in diverse samples of cancer
patients.11 The NIH PROMIS fatigue assessment has
been validated against the Fatigue Symptom Inven-
tory and the Functional Assessment of Chronic Illness
Therapy-Fatigue to measure fatigue severity and dis-
ruptiveness in cancer patients and cancer survivors.12,13
A three-to-five point change in fatigue T-score has
been estimated as clinically meaningful for cancer pa-
tients and across cancer type.12,14 Administration of
the NIH PROMIS fatigue survey included computer-
ized adaptive testing (CAT) for Cohort #1 and the
eight item short-form paper (version 1.0, Fatigue 8a)
for Cohort #2. The short form has been shown to be a re-
liable and precise alternative for CAT regarding psycho-
metric analysis of fatigue, with no differential effect on
the validity of scores across mode of assessment.15
The psychometric properties of the SF measures on
various cancer patients and survivors have been
assessed and shown to have good internal consistency
and validity.16 Clinically meaningful and statistically
significant postintervention differences following an
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exercise program have been reported as a change by 4–
15 T-score points.17,18
Biomarkers. Blood specimens were collected by a li-
censed phlebotomist between 7 and 9am following an
overnight fast at baseline, midpoint, and postinterven-
tion to measure serum concentrations of cortisol and
CRP. Serum was isolated by trained laboratory techni-
cians at the LMU Biomedical Sciences Laboratory and
stored at 80C. Cortisol (Abcam 108665; intra-assay
£9.0% coefficient of variation [CV], interassay £9.0%
CV) and CRP (Millipore HNDG2MAG-36; intra-
assay <10% CV, interassay <15% CV) were analyzed
from isolated serum at the Norris Comprehensive Can-
cer Center at the University of Southern California. All
blood specimens were deidentified and coded using a
nonpersonal, randomly assigned study identification
number.
Intervention
All assessments and exercise sessions were supervised
by a registered clinical exercise physiologist and by an
American College of Sports Medicine (ACSM) certified
health fitness specialist. Participants completed 60-min
sessions, three times a week for 26 weeks, that included
15 min of aerobic walking/running at 35–85% heart rate
reserve, 30 min of whole body circuit training, and
15 min of flexibility and core training as prescribed in
accordance with the Guidelines for Exercise for Cancer
Survivors from the ACSM.19 Each participant wore a
Polar heart rate monitor (Polar Electro, Lake Success,
NY) for assessments and exercise sessions, and all as-
sessment and training staff were trained in First Aid
and certified in cardio-pulmonary resuscitation.
Data analysis
Data from both cohorts were pooled given the high de-
gree of similarity in the source population for participant
recruitment and in data collection and intervention pro-
tocols. Analysis of Cohort #1 is based on 33 enrolled par-
ticipants with 21 (64%) completing the intervention.
Analysis of Cohort #2 is based on 43 enrolled partici-
pants with 35 (81%) completing the intervention.
Cohort #1 and Cohort #2 were implemented in sequen-
tial order and separated by a 3-month gap and 13 partic-
ipants from Cohort #1 also enrolled in Cohort #2. In
pooled analyses, data from these 13 participants in Cohort
#2 (30%) were excluded to ensure that each data point
is independent and to avoid potential bias from training
effects. This yields 63 unique enrolled participants in
the pooled analysis with 46 (73%) completing the inter-
vention. Reasons reported for attrition included trans-
portation limitations, work schedules, return to cancer
treatment, and post-treatment reconstructive surgery.
Participation in exercise training was recorded in-
person at each exercise session and used to calculate a
cumulative percent participation in training. For strati-
fied analysis, participation was defined as £50% of ses-
sions attended, 51–74% attended, and ‡75% attended.
Participants self-reported clinical diagnosis of chronic
conditions, which was combined to define comorbidity
as presence of 0, 1, 2, or >2 chronic conditions. BMI
was divided into normal weight (18.35–24.9; one partic-
ipant did not reach standard 18.5 cutpoint), overweight
(25–29.9), and obese (‡30) categories based on the
widely accepted ACSM cutpoints.20
Recovery from cancer treatment is nonlinear, and
the survivorship experience is unique to each individu-
al.21 The survivorship experience has been best articu-
lated as a series of seasons in which a cancer patient
moves from an acute stage of diagnosis and treatment
initiation, through an extended stage of treatment ces-
sation and navigating treatment-related side effects,
and into a permanent stage of lower risk of recurrence
but possibly with continued need to manage treatment-
related side effects.22
The transition from the acute stage to the extended
stage is arguably the most difficult as the specialized
medical and psychosocial care provided during treat-
ment is withdrawn at treatment cessation.23 Survival
statistics are typically based on the number of cancer
patients that survive from diagnosis to 5- and 10-year
marks. These cutpoints, however, do not reflect trajec-
tory of improvement of HRQoL, which is the hallmark
of the extended stage of the survivorship experience.24
Furthermore, physiological stress and inflammation
(CRP, cortisol) can be greatly affected within months
of treatment cessation.25 Therefore, for this study, time
since treatment (TST) was categorized into three groups
(<1, 1–4, 5+ years) to more finely stratify the extended
stage based on reports of persistence of treatment-
related effects from 6 to 12 months after treatment ces-
sation and given the conventional use of 5 years as the
transition from the extended to the permanent stage.
All statistical analyses were conducted using SPSS ver-
sion 23 (IBM Corp., Armonk, NY). Statistical outliers
were first determined by SPSS and removed from the
data analysis. Results with and without outliers were
manually compared using box and normality plots and
to identify major deviations in findings and to ensure
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that no more than 10% of data were removed from anal-
ysis by SPSS. Sample sizes were fixed on previous partic-
ipant pools for cohort 1, 2, and pooled sections. For all
statistical and stratified analyses, alpha levels were set to
0.05, and power levels were set to 0.80 (Table 1). Either
Cohen’s d or Pearson’s r was determined for effect size
where analysis of variances (ANOVAs), t-tests, and mul-
tinomial regressions were significant.
Unpaired t-tests were used to determine differences
between pooled, preintervention PROMIS fatigue scores
and waistline circumference, baseline cortisol, baseline
CRP, and postintervention fatigue scores. Unpaired t-
tests were also used in pooled comparisons between
waist circumference and baseline CRP and cortisol values.
A paired t-test was used to compare baseline waist circum-
ference with postintervention waist circumference scores.
One-way ANOVA was used to determine differences
between pooled, preintervention PROMIS fatigue
scores and TST, perceived physical activity, number
of comorbidities, participation, and treatment type
categories. Where ANOVAs were significant, Tukey’s
honest significant difference was used for post hoc
comparisons. Where homogeneity was violated,
Welch’s p was reported and Games–Howell post
hoc comparisons were used.
One-way ANOVAs were used for comparisons
between TST groups, comorbidity and physical com-
ponent summary (PCS), mental component sum-
mary (MCS), and all eight SF-36 domains. One-way
ANOVAs were also used in pooled comparisons be-
tween baseline CRP levels with TST, BMI, and waist
circumference groups and postintervention CRP
levels with TST groups. Finally, one-way ANOVAs
were used for baseline cortisol comparisons with
TST, BMI, and comorbidity.
For stratified analyses, one-way analysis of covari-
ance was used to determine the effect of covariates
(baseline scores) on postintervention measures for fa-
tigue, cortisol, CRP, PCS, MCS, and all eight SF-36 do-
mains while controlling for BMI, comorbidity, TST,
cancer treatment type, and race.
Results
Participants were, on average, college-educated women
in their early-to-mid 60s with at least two diagnosed
chronic conditions in addition to a cancer diagnosis
(Table 2). The majority of participants identified as
white, and approximately one-third identified with a his-
torically underrepresented racial minority group. Given
that the majority of participants were women, the most
represented cancer types were breast and gynecologic can-
cers (Table 2). Before the intervention, 25.4% participants
self-reported their physical activity level as very good or
good, whereas 74.6% of participants reported okay or
needs improvement.
NIH PROMIS fatigue
At baseline, PROMIS fatigue scores were significantly
worse for participants completing treatment within
the last year compared to those with a TST greater
than 5 years ( p = 0.038; r = 0.323), suggesting a greater
burden of fatigue among survivors that have more re-
cently completed cancer treatment. Those who per-
ceived their physical activity level as very good had
significantly better fatigue scores ( p = 0.039; r = 0.355)
compared to those who reported needs improvement.
Table 1. Power Analysis (a = 0.05)
Variables Statistical test Effect size Power
Baseline fatigue, TST ANOVA 0.323 0.602
Physical activity, baseline fatigue ANOVA 0.355 0.691
TT, baseline fatigue ANOVA 0.248 0.491
Baseline WC, baseline fatigue Unpaired t-test r = 0.832 Cohen’s d = 3.00 0.99
Baseline cortisol, baseline fatigue Unpaired t-test r = 0.382 Cohen’s d = 0.828 0.847
Baseline CRP, baseline fatigue Unpaired t-test r = 0.780 Cohen’s d = 2.49 0.99
Baseline fatigue, postintervention fatigue Unpaired t-test r = 0.844 Cohen’s d = 3.15 0.996
Participation, postintervention fatigue ANOVA 0.217 0.304
TST, baseline general health ANOVA 0.468 0.591
TST, baseline bodily pain ANOVA 0.393 0.443
Baseline CRP, TST ANOVA 0.209 1.00
BMI, baseline CRP ANOVA 0.541 1.00
Baseline WC, baseline CRP Unpaired t-test r = 0.780 Cohen’s d = 2.49 0.98
Postintervention CRP, TST ANOVA 0.084 0.415
Baseline cortisol, baseline WC Unpaired t-test r = 0.382 Cohen’s d = 0.828 0.553
Baseline cortisol, comorbidity ANOVA 0.114 0.079
ANOVA, analysis of variance; BMI, body mass index; CRP, c-reactive protein; TST, time since treatment; TT, treatment type; WC, waist circumference.
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Comorbid burden was not associated with fatigue
scores, but there was a difference in fatigue scores
between no chemotherapy and chemotherapy treatment
groups ( p = 0.043; r = 0.248). At baseline, a positive rela-
tionship was observed with waist circumference and
fatigue ( p < 0.0001; r = 0.832; d = 3.00). Fatigue scores
were also associated with baseline cortisol ( p < 0.0001;
r = 0.382; d = 0.828) and CRP levels ( p < 0.0001; r =
0.780; d = 2.49).
After 26 weeks of exercise intervention, self-reported
NIH PROMIS fatigue scores for the pooled cohort im-
proved by a noteworthy two points ( p = 0.092). There ap-
pears to be a dose–response relationship between percent
of sessions attended during the intervention and improve-
ment in self-reported fatigue scores (Fig. 1), although re-
sults lost significance at an alpha of 0.05 when controlling
for baseline scores ( p = 0.178). In stratified analysis, base-
line BMI, comorbidity, TST, cancer treatment type, and
race had no observable modifying effect on the relation-
ship between participation and fatigue.
SF-36 HRQoL survey
Among Cohort #2 participants, baseline TST was in-
versely related to baseline physical function ( p = 0.068)
and baseline general health ( p = 0.007; r = 0.468), sug-
gesting that those with longer TST had worsened physi-
cal function and general health. TST was positively
associated with bodily pain ( p = 0.026; r = 0.393), sug-
gesting greater self-reported pain in those furthest from
treatment cessation. No observable TST relationship
was detected for physical role, vitality, social function,
emotional role, mental health, PCS, and MCS. Comorbid
burden was inversely related to vitality ( p = 0.019) and
physical function ( p = 0.0827). However, no associations
were identified for comorbid burden and physical role,
bodily pain, general health, social function, emotional
role, mental health, or MCS.
Participants in Cohort #2 that reported a higher
comorbid burden at baseline appeared to experience
the greatest improvements in the SF-36 vitality domain
after 26 weeks of CART ( p = 0.019). Significant pre- to
postintervention improvements in self-reported bodily
pain ( p = 0.006) and limitations in social functioning
( p = 0.034) were also observed (Table 3). No significant
postintervention changes were identified for the remain-
ing five SF-36 domains (Table 3).
Postintervention changes in bodily pain appeared to
be mediated by TST ( p = 0.013), but not modified by
Table 2. Demographics of Participants at Baseline
Variable Cohort #1 (n = 33) Cohort #2 (n = 43) p
Age (mean years – SD) 61 – 12.58 65 – 7.39 0.080
Sex, male 6 (18%) 1 (2%) 0.017*
Sex, female 27 (82%) 42 (98%)
Race
White 20 (61%) 29 (67%) 0.585
African American, Hispanic 11 (33%) 10 (23%)
Other/multiracial 2 (6%) 4 (10%)
Education
High school education 2 (6%) 3 (7%) 0.958
Some college 10 (30%) 14 (33%)
4-Year college education 21 (64%) 26 (60%)
Employment status
Employed 9 (27%) 10 (23%) 0.552
Retired 11 (33%) 21 (49%)
Unemployed 3 (9%) 2 (5%)
Disabled/other support 10 (31%) 10 (23%)
Time since treatment (mean years – SD) 4.30 – 8.26 6.93 – 3.84 0.071
Cancer type
Breast 17 (52%) 13 (30%) <0.001*
Colorectal 7 (21%) 2 (5%)
Myeloma/lymphoma 3 (9%) 3 (7%)
Gynecologic 2 (6%) 22 (52%)
Thyroid 2 (6%) 1 (2%)
Prostate 1 (3%) 1 (2%)
Skin 1 (3%) 0 (0%)
Lung 0 (0%) 1 (2%)
Diagnosed chronic conditions (mean – SD) 2.34 – 0.74 2.37 – 1.64 0.920
*Statistically significant at a = 0.05.
SD, standard deviation.
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baseline BMI, comorbid burden, cancer treatment type,
and race. The observed postintervention change in so-
cial functioning was not modified by TST. Improve-
ments in all SF-36 domains appeared to be related to
frequency of participation in the intervention in a
dose–response manner; however, none of the dose–re-
sponse relationships were significant at an alpha of 0.05
(Fig. 2). Postintervention SF-36 domain scores from
Cohort #1 were not different than those from Cohort
#2 (Table 4). The mental health and physical health
summary scores (MCS and PCS, respectively) did not
differ significantly between cohorts after the 26-week
intervention (Table 5).
C-reactive protein
At baseline, mean CRP levels were lower in the <1 year
TST group compared to the 1–4 year (Welch’s p = 0.0250)
and 5+ year (Welch’s p = 0.009) TST groups (Table 6). A
positive relationship was observed between waist circum-
ference and CRP ( p < 0.0001; r = 0.780; d = 2.49) and be-
tween BMI and CRP (Welch’s p < 0.0001; r = 0.541) at
baseline. However, the relationship between baseline
FIG. 1. Effect of participation frequency on NIH PROMIS fatigue domain scores after 26 weeks of group
exercise, The IMPAACT Study 2014–2016, n = 49. IMPAACT, Improving Physical Activity After Cancer
Treatment; NIH PROMIS, National Institutes of Health’s Patient Reported Outcomes Measurement
Information System.








Vitality 51.15 (10.81) 51.40 (10.40) 0.25 (0.41) 0.890
Bodily pain 50.54 (9.51) 48.20 (10.07) 2.34 (0.56) 0.006*
Mental health 52.96 (7.66) 52.40 (9.91) 0.56 (2.25) 0.546
Physical functioning 48.73 (7.64) 47.03 (8.75) 1.70 (1.11) 0.077
Social functioning 50.60 (9.17) 47.75 (11.66) 2.85 (2.49) 0.034*
Emotional roles 50.59 (6.81) 49.50 (10.05) 1.09 (3.24) 0.441
Physical roles 47.46 (10.84) 46.69 (10.51) 0.77 (0.33) 0.659
General health 52.88 (9.91) 54.29 (9.98) 1.41 (0.07) 0.156
PCS 48.73 (10.14) 48.04 (9.18) 0.69 (0.96) 0.457
MCS 52.63 (8.07) 51.82 (10.25) 0.81 (2.18) 0.466
*Statistically significant at a = 0.05.
MCS, mental component summary; PCS, physical component summary.
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waist circumference and CRP lost significance after
controlling for TST ( p = 0.815).
Collectively, this cross-sectional analysis suggests a
synergism among the CRP, TST, and waist circumfer-
ence variables among cancer survivors that differ from
the expected linear CRP and waist circumference (cen-
tral adiposity) relationship observed in cancer-free
adults. There was no observable relationship between
age and CRP levels or between comorbid burden and
CRP levels at baseline.
Following the 26-week intervention, waist circum-
ference decreased on average by 3.40 cm ( p = 0.0002).
A mean decrease of 1.64 – 10.11 mg/L in CRP levels
was also observed in the combined cohort (Fig. 3). Par-
ticipants who were within 1 year of treatment comple-
tion experienced greater improvements in post CRP
levels compared to those who had treatment from 1
to 4 years (Welch’s p = 0.030) and 5 or more years
ago (Welch’s p = 0.023). The dose–response relation-
ship between participation and decreases in CRP was
not mediated by treatment type.
Cortisol
In the pooled analysis, baseline cortisol levels were not
associated with TST nor found to be significantly differ-
ent than postintervention cortisol levels (Table 6). No as-
sociation was detected between baseline cortisol and BMI
category, but a positive correlation was observed with
waist circumference ( p < 0.0001; r = 0.382; d = 0.828),
suggesting a role for central adiposity. A positive associ-
ation was observed between comorbid burden and base-
line cortisol levels ( p < 0.0001; r = 0.114), indicating that
FIG. 2. Effect of participation frequency on SF-36 domains after 26 weeks of group exercise, The IMPAACT
Study 2015–2016 (Cohort #2), n = 35.
Table 4. SF-36 Subscale and Summary Score Assessments: Cohort Comparison
Subscale measure
Cohort #1 (n = 15)
postintervention mean (SD)




Vitality 50.22 (11.0) 51.40 (10.40) 1.18 (0.6) 0.719
Bodily pain 48.88 (8.51) 48.20 (10.07) 0.68 (1.56) 0.820
Mental health 51.04 (8.53) 52.40 (9.91) 1.36 (1.38) 0.645
Physical functioning 48.13 (9.38) 47.03 (8.75) 1.10 (0.63) 0.691
Social functioning 47.65 (9.17) 47.75 (11.66) 0.10 (2.49) 0.976
Emotional roles 49.44 (7.49) 49.50 (10.05) 0.06 (2.56) 0.983
Physical roles 48.47 (9.05) 46.69 (10.51) 1.78 (1.46) 0.570
General health 53.91 (9.33) 54.29 (9.98) 0.38 (0.65) 0.900
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participants with multiple comorbidities were more likely
to experience high cortisol levels.
Discussion
Summary of findings
At baseline, 75% of this study’s participants reported an
average or below average perception of their physical
activity levels. In addition, participants with poorer
perceptions of their physical activity levels were more
likely to have completed treatment recently. This find-
ing is consistent with Gjerset et al. who found that
among cancer survivors experiencing chronic fatigue,
86% desired physical training compared to 65% of sur-
vivors without chronic fatigue.26
Self-reported fatigue was particularly noteworthy
among participants who received chemotherapy and
positively associated with increased baseline body
weight and cortisol levels. It was also noted that partic-
ipants with higher self-reported comorbidity had
higher cortisol levels and decreased vitality and physi-
cal function, observations consistent with poorer qual-
ity of life due to multiple medical conditions and the
stress of navigating poorer health. However, participants
with multiple chronic conditions experienced the most
noteworthy postintervention improvement in bodily
pain, social functioning, and vitality.
Self-reported NIH PROMIS fatigue scores improved
marginally with increased participation in the 26-week
intervention by a noteworthy two points. Participants
also improved self-reported bodily pain and limitations
in social functioning following 26 weeks of CART.
These findings support previous studies in the adult
breast cancer survivor population that found improve-
ments in SF-36 domains following a resistance training
program,27 an aerobic exercise program,18 or an exer-
cise education program.17
The role of social support
The peer affirmation and social support received dur-
ing this group exercise intervention may have posi-
tively influenced the perception of their health and
physical ability. Social support could provide a benefi-
cial effect due to continued positive experiences and so-
cially rewarded actions in the exercise intervention.
Support from a social network is related to positive
physical health outcomes through neuroendocrine
changes.28
This social support may have also contributed to
the high program adherence demonstrated through-
out the intervention. Fraser and Spink showed high
exercise intervention compliance in adult females
that valued the role of social support.29 Likewise,
Nock et al. interviewed breast cancer survivors follow-
ing a group exercise program and found that social







Cohort #1 (n = 15) 49.19 (9.32) 50.35 (9.58) 0.739
Cohort #2 (n = 35) 48.04 (9.18) 51.82 (10.25) 0.114
Table 6. Mean Values of Pre- and Postoutcome Variables and Mean Values of Pre- and Postoutcome Variables
by Time Since Treatment Group
Outcome variable TST group
Pre (0 weeks) Post (26 weeks)
Mean (SD) p Mean (SD) p
CRP (mg/L) — 21.45 (22.82) — 28.97 (39.13) 0.210
<1 year 7.27 (4.50) 0.025a,* 4.73 (3.84) 0.030a,*
1–4 years 25.27 (26.76) 0.955b 34.91 (40.08) 0.726b
5+ years 23.02 (24.04) 0.009c,* 25.32 (33.70) 0.023c,*
Cortisol (ng/mL) — 162.17 (89.44) — 173.00 (101.60) 0.556
<1 year 193.15 (91.62) 0.317a 150.10 (42.42) 0.978a
1–4 years 143.01 (66.72) 0.663b 62.11 (16.03) 0.987b
5+ years 166.56 (106.20) 0.699c 163.33 (76.45) 0.950c
Waist circumference (cm) — 94.94 (17.61) — 91.54 (15.26) 0.0002**
<1 year 99.30 (14.19) 0.931a 90.70 (15.44) 0.991a
1–4 years 97.01 (20.03) 0.896b 91.73 (16.67) 1.000b
5+ years 94.47 (17.98) 0.715c 90.68 (15.33) 0.977c
aPost hoc comparison between <1 and 1–4 year groups.
bPost hoc comparison between 1–4 and 5+ year groups.
cPost hoc comparison difference between <1 and 5+ year groups.
*Significant difference between post hoc comparison ( p < 0.05).
**Significant difference between pre- and postoutcome variable ( p < 0.05).
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support was one of three primary motivators to en-
gage in the program.30
Mediators of stress-related biomarkers
In addition to examining the potential for improving
HRQoL and perceived barriers with exercise among
cancer survivors, this study also contributes new in-
sight into how the anti-inflammatory effects of exercise
and reduction of CRP may be mediated by body com-
position and TST.5 The intervention appeared to have
the greatest impact on reducing CRP levels among par-
ticipants that had most recently completed treatment,
which underscores the greater opportunity for im-
provement with earlier intervention post-treatment.
CRP levels also responded positively to exercise inter-
vention among those participants with normal baseline
levels of CRP, which is consistent with previously pub-
lished studies.31,32
Exercise did not appear to have a substantial effect
on CRP among those cancer survivors with above nor-
mal baseline levels of CRP. The abnormal CRP levels
(>3.0 mg/L) are indicative of chronic inflammation
and might be related to a participant’s treatment regi-
men, body weight, or a combination of both.33 This
suggests a need to further examine CRP levels specifi-
cally in cancer survivors to establish a separate scale
for average CRP level by body weight, TST, treatment
type, and cancer type.
Currently, levels above 10 mg/mL are considered in-
dicative of acute inflammation, and levels above 25 mg/
mL are excluded from analysis as too extreme.34 How-
ever, this exclusionary approach may not be ideal for a
population of cancer survivors and may limit the full
elucidation of the CRP response pathway. In addition,
before the intervention cortisol levels were positively as-
sociated with waist circumference. Thus, more attention
to the influence of body composition on stress-related
inflammation is needed given that the body composition
of most adults, especially postmenopausal women, shifts
toward increases in visceral fat mass with aging.
Given that previously published studies of different
exercise modalities report a mixture of outcomes regar-
ding CRP and inflammatory mediators,35 it is possible
that survivors with unique biomarker profiles may
need more specific exercise prescriptions for aerobic
and resistance training.
Conclusions
This study had multiple strengths, including above aver-
age study compliance rates, completion of both per-
ceived and physiological measures of fatigue and stress,
and inclusion of covariates, including comorbid burden
FIG. 3. Effect of CART participation frequency on CRP and cortisol biomarkers after 26 weeks of group
exercise, The IMPAACT Study 2014–2016, n = 46. CART, combined aerobic and resistance training; CRP,
c-reactive protein.
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and TST in analysis. The length of this intervention was
longer than the majority of previous cancer survivorship
studies and included a novel group exercise design.
Acceptability to the intervention is demonstrated by
an average participation of 73% for the pooled cohort,
despite complications that would be expected for an
older and medically complex population. The differ-
ence in participation between the two cohorts might
be explained by times that sessions were offered.
Cohort #1 participants were given the option of partici-
pating in either a noon or 5pm session. Cohort #2 par-
ticipants were given the option of participating in
either a 10am or a noon session, and since Cohort #2
had more retired individuals, this may have helped
with attrition.
Despite the encouraging results demonstrated in the
study, there are limitations that must be considered.
First, results may not be generalizable to other cancer
populations given the small sample size and narrow
range of cancer types included in this study. A control
group may have strengthened our findings, however,
the primary aim was to determine if there was a dose-
dependent response between participation and change
in outcome measures. This allowed comparison between
frequently attending and low attending participants as
an internal control/stratum.
In conclusion, this study suggests that starting an ex-
ercise program would be of greatest benefit to those pa-
tients who have most recently completed treatment and
who have received chemotherapy in particular. The
findings from this study suggest a complex relationship
between treatment, body weight, fatigue, and biomark-
ers of stress and inflammation. The intricate mapping
of the relationships between stress-related inflamma-
tion, exercise interventions, and perceived HRQoL
among cancer survivors is still being developed, and
larger studies will be needed to establish the temporal-
ity and directionality of these relationships.
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